Immunotherapy

Immunotherapy

Antitumour immunotherapy is based on the principle that tumours can sometimes escape immune response/checkpoints owing to adaptations in immune surveillance and the tumour microenvironment. Immunotherapy represents a change in the treatment paradigm. The pathway of the programmed death receptor-1 (PD-1) and its ligand (PD-L1) has become an increasingly important target for immunotherapy in HNSCC. The receptor–ligand interaction is a major mechanism used by tumours to evade the imm une system. Multiple randomised phase III trials have demonstrated that exposure to a PD-1 inhibitor prolongs sur vival in recurrent or metastatic HNSCC. These results, among others, highlight the potential for research assessing the role of checkpoint inhibition in the man agement of HNSCC. Immunotherapy

Antitumour immunotherapy is based on the principle that tumours can sometimes escape immune response/checkpoints owing to adaptations in immune surveillance and the tumour microenvironment. Immunotherapy represents a change in the treatment paradigm. The pathway of the programmed death receptor-1 (PD-1) and its ligand (PD-L1) has become an increasingly important target for immunotherapy in HNSCC. The receptor–ligand interaction is a major mechanism used by tumours to evade the imm une system. Multiple randomised phase III trials have demonstrated that exposure to a PD-1 inhibitor prolongs sur vival in recurrent or metastatic HNSCC. These results, among others, highlight the potential for research assessing the role of checkpoint inhibition in the man agement of HNSCC.